PTK2 and pancreatic ductal adenocarcinoma: GSK2256098 is an inhibitor targeting the FAK Tyr397 site In recent years, preclinical studies on GSK2256098 have found that it inhibits cell proliferation, migration and invasion of renal cell carcinoma [64], uterine cancer [65] and pancreatic ductal adenocarcinoma [66], and leads to lower tumor weight and less metastasis in mouse models.